US20160095307A1 - Method and composition for hypothermic storage of placental tissue - Google Patents

Method and composition for hypothermic storage of placental tissue Download PDF

Info

Publication number
US20160095307A1
US20160095307A1 US14/508,398 US201414508398A US2016095307A1 US 20160095307 A1 US20160095307 A1 US 20160095307A1 US 201414508398 A US201414508398 A US 201414508398A US 2016095307 A1 US2016095307 A1 US 2016095307A1
Authority
US
United States
Prior art keywords
solution
placental membrane
membrane
tissue
placental
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/508,398
Other languages
English (en)
Inventor
Jeremy B. Vines
Katie C. Mowry
Howard P. Walthall, JR.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prime Merger Sub LLC
Original Assignee
Nutech Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Assigned to NuTech Medical, Inc. reassignment NuTech Medical, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MOWRY, KATIE C., VINES, JEREMY B., WALTHALL, HOWARD P., JR.
Priority to US14/508,398 priority Critical patent/US20160095307A1/en
Application filed by Nutech Medical Inc filed Critical Nutech Medical Inc
Priority to ES15849362T priority patent/ES2913155T3/es
Priority to PT158493627T priority patent/PT3203835T/pt
Priority to DK15849362.7T priority patent/DK3203835T3/da
Priority to AU2015328092A priority patent/AU2015328092B2/en
Priority to EP22160442.4A priority patent/EP4035530A1/fr
Priority to PCT/US2015/054494 priority patent/WO2016057669A1/fr
Priority to EP15849362.7A priority patent/EP3203835B1/fr
Priority to JP2017518297A priority patent/JP6595588B2/ja
Priority to US14/972,459 priority patent/US20160101135A1/en
Priority to US14/972,535 priority patent/US20160100571A1/en
Priority to US15/073,125 priority patent/US20160192639A1/en
Publication of US20160095307A1 publication Critical patent/US20160095307A1/en
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PRIME MERGER SUB, LLC
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PRIME MERGER SUB, LLC
Assigned to PRIME MERGER SUB, LLC reassignment PRIME MERGER SUB, LLC MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NuTech Medical, Inc., PRIME MERGER SUB, LLC
Assigned to SILICON VALLEY BANK reassignment SILICON VALLEY BANK TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT Assignors: PRIME MERGER SUB, LLC
Priority to US17/974,395 priority patent/US20230077597A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0236—Mechanical aspects
    • A01N1/0242—Apparatuses, i.e. devices used in the process of preservation of living parts, such as pumps, refrigeration devices or any other devices featuring moving parts and/or temperature controlling components
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0236—Mechanical aspects
    • A01N1/0263—Non-refrigerated containers specially adapted for transporting or storing living parts whilst preserving, e.g. cool boxes, blood bags or "straws" for cryopreservation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly

Definitions

  • placental membrane uses for scaffolding or providing structure for the regrowth of cells and tissue.
  • An important advantage of placental membrane in scaffolding is that the amnion contains an epithelial layer.
  • the epithelial cells derived from this layer are similar to stem cells, allowing the cells to differentiate into cells of the type that surrounds them.
  • Multipotent cells similar to stem cells are also contained within the body of the amniotic membrane.
  • the amniotic membrane contains various growth and trophic factors, such as epidermal, insulin-like, and fibroblast growth factors, as well as high concentrations of hyaluronic acid, which may be beneficial to prevent scarring and inflammation and to support healing.
  • placental membrane offers a wide variety of beneficial medical uses.
  • Cell-based therapies have considerable potential for the repair and regeneration of tissues.
  • the addition of a scaffold to these cell-based therapies has yielded improved outcomes [Krishnamurithy G., et al. J Biomed Mater Res Part A, 99A:500-506 (2011)].
  • the material used for the scaffold will be biocompatible such that it provokes little to no immune response, biodegrades, and is available in sufficient quantities to be practical.
  • the placental membrane has long been identified as a material potentially filling this role in the clinic, efforts have been limited to in vitro studies, impractical in vivo techniques, or have yielded less-than-optimal outcomes.
  • the conditions under which the scaffold is used may have a dramatic effect on the therapeutic efficacy.
  • Osmolality is a colligative property and dependent on the amount of ions present within solution as opposed to their size or nature [Taylor M. J., Physico - chemical principles in low temperature biology , in T HE E FFECTS OF L OW T EMPERATURES ON B IOLOGICAL S YSTEMS , B. W. W. Grout & G. J. Morris, Editors. 1987, Edward Arnold: London. pp. 3-71.].
  • the ATP consumption required to perform the active transport reactions are adapted to occur at normal body temperature. At hypothermic temperatures, the active transport pumps are unable to bind to ATP to process it as energy.
  • hypothermic storage media should be slightly hypertonic to counteract this change.
  • Oxygen is necessary for the process of aerobic respiration and the production of adenosine triphosphate (ATP), the main energy source utilized by cells.
  • ATP adenosine triphosphate
  • Oxygen is necessary for the process of aerobic respiration and the production of adenosine triphosphate (ATP), the main energy source utilized by cells.
  • ATP adenosine triphosphate
  • ATP is depleted within a few minutes. This depletion leads to a shift from aerobic to anaerobic metabolism which is self-limiting and causes the production of lactate and protons. This leads to a cascade eventually culminating in necrosis and cell death.
  • Oxygen-Derived Free Radicals ODFRs
  • the present invention is directed to both compositions and methods related to the hypothermic storage of tissue.
  • a composition of hypothermic storage media that includes DMEM and albumin.
  • a method of hypothermically storing tissue includes the steps of preparing or obtaining media containing DMEM and albumin, placing tissue into the media, and storing the tissue and media hypothermically.
  • a method for wound treatment includes the steps of storing tissue in hypothermic storage media and applying the tissue to the site of the wound. The tissue may also be minced or ground into particles, which may be injected into the site of the wound.
  • FIG. 1A is a graph illustrating preliminary cell viability assessment.
  • FIG. 1B is a quantitative image of cell viability.
  • FIG. 1C is an additional quantitative image of cell viability.
  • FIG. 1D is an additional quantitative image of cell viability.
  • FIG. 2A is a graph showing the viability of placental membrane cells at 42 days.
  • FIG. 2B is an additional graph showing the viability of placental membrane cells at 42 days.
  • FIG. 2C is an additional graph showing the viability of placental membrane cells at 42 days.
  • FIG. 4B is an illustration of the macroscopic handling characteristics of tissue stored in a DMEM+recombinant human albumin (rhA) solution.
  • FIG. 5A is an illustration of histological staining of tissues stored in a DMEM solution for four weeks.
  • FIG. 5B is an illustration of histological staining of tissues stored in a DMEM+rhA solution for four weeks.
  • FIG. 5C is an illustration of histological staining of tissues stored in a DMEM solution for six weeks.
  • FIG. 5D is an illustration of histological staining of tissues stored in a DMEM+rhA solution for six weeks.
  • FIG. 5F is a graph illustrating the concentration of tissue inhibiting matrix metalloproteinases in placental membrane cells.
  • FIG. 7C is an additional illustration of wounds treated with experimental placental membranes nine days post-procedure.
  • FIG. 7D is an additional illustration of wounds treated with experimental placental membranes nine days post-procedure.
  • FIG. 9B is an additional illustration of wounds treated with experimental placental membranes twenty-one days post-procedure.
  • FIG. 9C is an additional illustration of wounds treated with experimental placental membranes twenty-one days post-procedure.
  • FIG. 11D is an illustration of the histological examination of a wound treated with dehydrated mesh twenty-one days post-procedure.
  • FIG. 12B is an additional illustration of the histological examination of a wound treated with dehydrated mesh twenty-one days post-procedure.
  • FIG. 12C is an additional illustration of the histological examination of a wound treated with dehydrated amnion twenty-one days post-procedure.
  • FIG. 12D is an additional illustration of the histological examination of a wound treated with dehydrated amnion twenty-one days post-procedure.
  • FIG. 13C is a quantification of follicle/gland formation in wounds treated with experimental placental membranes at nine and twenty-one days post-procedure.
  • ranges can be expressed as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, an embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by the use of “about,” it will be understood that the particular value forms another embodiment. It will be understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. It will also be also understood that there are a number of values disclosed herein, and that each value is also disclosed herein as “about” that particular value in addition to the value itself. For example, if the value “50” is disclosed, then “about 50” is also disclosed.
  • amniotic tissue means amniotic fluid cells, placental membrane, amnion tissue or combinations thereof.
  • placental membrane and amnion tissue refer to one or more layers of the placental membrane.
  • placental membrane or amnion tissue may refer to a placental membrane comprising both the amniotic and chorionic layers.
  • placental membrane or amnion tissue may refer to a placental membrane in which the chorion has been removed.
  • placental membrane or amnion tissue may refer to a placental membrane in which the epithelial layer has been removed.
  • the amnion tissue component of the placental membrane preparation is produced from placentas collected from consenting donors in accordance with the Current Good Tissue Practice guidelines promulgated by the U.S. Food and Drug Administration.
  • the intact placenta is retrieved, and the placental membrane is dissected from the placenta.
  • the placental membrane is cleaned of residual blood, placed in a bath of sterile solution, stored on ice and shipped for processing.
  • the placental membrane is rinsed to remove any remaining blood clots, and if desired, rinsed further in an antibiotic rinse [Diaz-Prado S. M., et al. Cell Tissue Bank, 11:183-195 (2010)].
  • the placental membrane preparation may include a processed cartilage selected from the group consisting of a ground cartilage, a minced cartilage, a cartilage paste and combinations thereof.
  • the processed cartilage may be an autograft cartilage, an allograft cartilage or combinations thereof.
  • the processed cartilage is preferably provided in between a 3:1 and a 1:3 ratio by volume to the original membrane preparation.
  • the minced, ground or morselized membrane particles may have an average particle size of less than about 1.5 mm and are absorbed to a collagen matrix.
  • the collagen matrix may them be used in a method of treating wounds, as will be described in more detail below.
  • the placental membrane preparation may include hyaluronic acid, saline or a combination thereof.
  • Hyaluronic acid and saline may be included with the placental membrane preparation when it is desired to inject the preparation into a skeletal joint.
  • the hyaluronic acid or saline is preferably provided in a 2:1 or 1:1 ratio by volume to the original membrane preparation.
  • the placental membrane preparation may include one or more biocompatible glues.
  • Biocompatible glues are natural polymeric materials that act as adhesives. Biocompatible glues may be formed synthetically from biological monomers such as sugars and may consist of a variety of substances, such as proteins and carbohydrates. Proteins such as gelatin and carbohydrates such as starch have been used as general-purpose glues for many years.
  • the biocompatible glue is fibrin glue, such as Tisseel. Fibrin is made up of fibrinogen (lyophilized pooled human concentrate) and may also include thrombin (which may be reconstituted with calcium chloride).
  • the membrane may be stored in a hypothermic storage solution allowing the preservation of the viability of the membrane cells.
  • the solution presently described is effective in storing tissues at temperatures above freezing, for instance at a temperature ranging from 0° C. to 20° C. In an additional embodiment, the solution is effective at temperatures ranging between more than 0° C. and less than 10° C.
  • the hypothermic storage solution may include a commercially available tissue culture media with appropriate supplements. All components of the solution are chemically defined/cGMP compliant and free of both xeno-derived and human-derived components.
  • the tissue culture media comprises DMEM.
  • the hypothermic storage solution of the present invention further includes supplementation with appropriate buffers to maintain physiological pH despite changes in carbon dioxide concentration produced by cellular respiration.
  • the buffer comprises HEPES buffer (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), a zwitterionic organic chemical buffering agent.
  • HEPES is widely used in cell culture, largely because it is better at maintaining physiological pH as compared to bicarbonate buffers.
  • the HEPES buffer may be used at a concentration as will be known to one of skill in the art, for example from about 20 mM to 30 mM. In one embodiment, the solution contains a concentration of 25 mM HEPES.
  • the addition of the human plasma albumin acts to maintain activity of tissue inhibiting matrix metalloproteinases (TIMPs) 1, 2 and 4.
  • TIMPs are known inhibitors of matrix metalloproteinases (MMPs), which are responsible for enzymatically breaking down various ECM proteins. Maintenance of TIMP activity, and reduction of extracellular matrix proteins, could act to preserve membrane activity over time.
  • MMPs matrix metalloproteinases
  • the placental membrane preserved in the storage solution described herein has a total TIMP 1, 2 and 4 concentration of more than 400 ng per mg of placental membrane following twenty-four hours of storage in the hypothermic storage solution of the invention.
  • the placental membrane may be stored within the hypothermic solution for an extended period of time without freezing the membrane. In this embodiment, the membrane is not frozen prior to or after being hypothermically stored in the solution.
  • T is the total protein content
  • P is the concentration of each protein
  • W is the weight of the tissue sample.
  • Placental membrane samples were examined for their effectiveness in promoting wound healing.
  • Four 15 mm diameter, full thickness wounds were created on the dorsal skin surface (i.e. the back) of three laboratory rats.
  • Four types of placental membrane preparations were placed stromal side down on the wounds of each animal—one type of membrane on each wound. The following types of membranes were utilized:
  • FIG. 11A preparations showed only slightly increased granulation and epithelialization as compared to the control.
  • the wound treated with the fresh stored placental membrane FIG. 11B
  • FIG. 12D illustrates this increased development of hair follicles and sebaceous glands as well as new collagen deposition and the formation of granulation tissue in the wound treated with the fresh stored placental membrane.
  • these developments are not present in the wounds treated with the control ( FIG. 12A ), the dehydrated mesh ( FIG. 12B ) or the dehydrated amnion ( FIG. 12C ) preparations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mechanical Engineering (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Thermal Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
US14/508,398 2014-10-07 2014-10-07 Method and composition for hypothermic storage of placental tissue Abandoned US20160095307A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US14/508,398 US20160095307A1 (en) 2014-10-07 2014-10-07 Method and composition for hypothermic storage of placental tissue
ES15849362T ES2913155T3 (es) 2014-10-07 2015-10-07 Procedimiento para el almacenamiento hipotérmico de tejido placentario
PT158493627T PT3203835T (pt) 2014-10-07 2015-10-07 Método para armazenamento hipotérmico de tecido placental
DK15849362.7T DK3203835T3 (da) 2014-10-07 2015-10-07 Fremgangsmåde til hypotermisk lagring af placentavæv
AU2015328092A AU2015328092B2 (en) 2014-10-07 2015-10-07 Method and composition for hypothermic storage of placental tissue
EP22160442.4A EP4035530A1 (fr) 2014-10-07 2015-10-07 Stockage hypothermique de tissu placentaire
PCT/US2015/054494 WO2016057669A1 (fr) 2014-10-07 2015-10-07 Procédé et composition pour conservation hypothermique de tissu placentaire
EP15849362.7A EP3203835B1 (fr) 2014-10-07 2015-10-07 Procédé pour conservation hypothermique de tissu placentaire
JP2017518297A JP6595588B2 (ja) 2014-10-07 2015-10-07 胎盤組織の低温貯蔵のための方法および組成物
US14/972,459 US20160101135A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US14/972,535 US20160100571A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US15/073,125 US20160192639A1 (en) 2014-10-07 2016-03-17 Method and Composition for Hypothermic Storage of Placental Tissue
US17/974,395 US20230077597A1 (en) 2014-10-07 2022-10-26 Method and composition for hypothermic storage of placental tissue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/508,398 US20160095307A1 (en) 2014-10-07 2014-10-07 Method and composition for hypothermic storage of placental tissue

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/972,535 Division US20160100571A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US14/972,459 Division US20160101135A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US15/073,125 Continuation US20160192639A1 (en) 2014-10-07 2016-03-17 Method and Composition for Hypothermic Storage of Placental Tissue

Publications (1)

Publication Number Publication Date
US20160095307A1 true US20160095307A1 (en) 2016-04-07

Family

ID=55631795

Family Applications (5)

Application Number Title Priority Date Filing Date
US14/508,398 Abandoned US20160095307A1 (en) 2014-10-07 2014-10-07 Method and composition for hypothermic storage of placental tissue
US14/972,535 Pending US20160100571A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US14/972,459 Abandoned US20160101135A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US15/073,125 Abandoned US20160192639A1 (en) 2014-10-07 2016-03-17 Method and Composition for Hypothermic Storage of Placental Tissue
US17/974,395 Pending US20230077597A1 (en) 2014-10-07 2022-10-26 Method and composition for hypothermic storage of placental tissue

Family Applications After (4)

Application Number Title Priority Date Filing Date
US14/972,535 Pending US20160100571A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US14/972,459 Abandoned US20160101135A1 (en) 2014-10-07 2015-12-17 Method and Composition for Hypothermic Storage of Placental Tissue
US15/073,125 Abandoned US20160192639A1 (en) 2014-10-07 2016-03-17 Method and Composition for Hypothermic Storage of Placental Tissue
US17/974,395 Pending US20230077597A1 (en) 2014-10-07 2022-10-26 Method and composition for hypothermic storage of placental tissue

Country Status (8)

Country Link
US (5) US20160095307A1 (fr)
EP (2) EP3203835B1 (fr)
JP (1) JP6595588B2 (fr)
AU (1) AU2015328092B2 (fr)
DK (1) DK3203835T3 (fr)
ES (1) ES2913155T3 (fr)
PT (1) PT3203835T (fr)
WO (1) WO2016057669A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021071430A1 (fr) * 2019-10-08 2021-04-15 Cellresearch Corporation Pte. Ltd. Formulation de stockage ou de transport de cellules souches mésenchymateuses et ses procédés de fabrication et d'utilisation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
CN107296041B (zh) * 2017-07-02 2020-12-25 江西瑞济生物工程技术股份有限公司 一种新鲜羊膜保存液及新鲜羊膜保存方法与应用
CN108684653A (zh) * 2018-03-23 2018-10-23 杭州联泽生物科技有限公司 一种胎盘保存液及其制备方法
CN109362709A (zh) * 2018-11-21 2019-02-22 江苏赛尔时代健康产业有限公司 一种胎盘组织保存液及其制备方法
JP7336784B2 (ja) * 2019-05-15 2023-09-01 国立大学法人富山大学 創傷接触部材

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612028A (en) * 1988-02-17 1997-03-18 Genethics Limited Method of regenerating or replacing cartilage tissue using amniotic cells
US20070128719A1 (en) * 2003-05-22 2007-06-07 Tissuetech, Inc. Isolation and expansion of animal cells in cell cultures
US20110206776A1 (en) * 2010-02-18 2011-08-25 Samson Tom Methods of manufacture of immunocompatible amniotic membrane products
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
US20130101562A1 (en) * 2011-05-03 2013-04-25 Immunovative Therapies Ltd. Methods for handling biological drugs containing living cells
US8932805B1 (en) * 2011-10-31 2015-01-13 BioDlogics, LLC Birth tissue material and method of preparation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492103B1 (en) * 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
EP2336299A1 (fr) * 2001-02-14 2011-06-22 Anthrogenesis Corporation Placenta post-gravidique de mammifere, son utilisation et cellules souches placentaires correspondantes
WO2004000164A2 (fr) * 2002-06-24 2003-12-31 Amniotech, Inc. Liberation de molecules bioactives mediee par la membrane amniotique
GB0514567D0 (en) * 2005-07-15 2005-08-24 Univ Nottingham Surgical membrane
EP2076279B1 (fr) * 2006-10-06 2014-08-27 Anthrogenesis Corporation Compositions de collagène de placenta humain et procédés de fabrication et d'utilisation de celles-ci
EP2630959A1 (fr) * 2007-02-12 2013-08-28 Anthrogenesis Corporation Traitement de maladies inflammatoires au moyen de cellules souches placentaires
US7960098B2 (en) * 2007-07-12 2011-06-14 Warsaw Orthoperic, Inc. Methods and compositions for the preservation of cells and tissues
AU2009228141A1 (en) * 2008-03-27 2009-10-01 Biolife Solutions, Inc. Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue
JP5796290B2 (ja) * 2010-12-03 2015-10-21 公益財団法人先端医療振興財団 膵島組織保存溶液及びそれを用いる方法
US20120207717A1 (en) * 2011-02-14 2012-08-16 Sing George L Methods for treating inhalation injury
US20130136773A1 (en) * 2011-09-30 2013-05-30 NuTech Spine, Inc. Expandable Placental Membrane and Methods of Making and Storing Same
US9192157B2 (en) * 2012-03-01 2015-11-24 Russell James Schweizer Tissue retrieval, storage, and explant culture device for the derivation of stem cells
US9560846B2 (en) * 2012-08-10 2017-02-07 Paragonix Technologies, Inc. System for hypothermic transport of biological samples
FR2996413B1 (fr) * 2012-10-10 2014-12-05 Maco Pharma Sa Procede pour conserver le sang placentaire
US20140212390A1 (en) * 2013-01-30 2014-07-31 NuTech Medical, Inc. Placental Membrane Preparation and Methods of Making and Using Same
US20150007919A1 (en) * 2013-01-31 2015-01-08 Wu Xi Jidaer Wheel Co., Ltd. Hinged type locking ring quick locking device
US9427273B2 (en) * 2013-02-20 2016-08-30 BioDlogics, LLC Biologic balloon and method of use
CN103789262A (zh) * 2014-02-17 2014-05-14 宁波普莱森特生物科技有限公司 一种临床应用级胎盘造血干细胞的制备方法及保存方法
AU2014393404A1 (en) * 2014-05-07 2016-11-24 Osiris Therapeutics, Inc. Immunocompatible amniotic membrane products
AU2014393403A1 (en) * 2014-05-07 2016-11-24 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612028A (en) * 1988-02-17 1997-03-18 Genethics Limited Method of regenerating or replacing cartilage tissue using amniotic cells
US20070128719A1 (en) * 2003-05-22 2007-06-07 Tissuetech, Inc. Isolation and expansion of animal cells in cell cultures
US8071135B2 (en) * 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
US20110206776A1 (en) * 2010-02-18 2011-08-25 Samson Tom Methods of manufacture of immunocompatible amniotic membrane products
US20130101562A1 (en) * 2011-05-03 2013-04-25 Immunovative Therapies Ltd. Methods for handling biological drugs containing living cells
US8932805B1 (en) * 2011-10-31 2015-01-13 BioDlogics, LLC Birth tissue material and method of preparation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021071430A1 (fr) * 2019-10-08 2021-04-15 Cellresearch Corporation Pte. Ltd. Formulation de stockage ou de transport de cellules souches mésenchymateuses et ses procédés de fabrication et d'utilisation
CN114867347A (zh) * 2019-10-08 2022-08-05 细胞研究私人有限公司 间充质干细胞的储存或运输制剂及其制备和使用方法

Also Published As

Publication number Publication date
AU2015328092A1 (en) 2017-04-27
PT3203835T (pt) 2022-05-11
EP3203835A4 (fr) 2018-03-07
ES2913155T3 (es) 2022-05-31
JP6595588B2 (ja) 2019-10-23
US20160100571A1 (en) 2016-04-14
EP3203835B1 (fr) 2022-04-06
DK3203835T3 (da) 2022-05-09
AU2015328092B2 (en) 2018-11-01
EP4035530A1 (fr) 2022-08-03
JP2017531653A (ja) 2017-10-26
WO2016057669A1 (fr) 2016-04-14
US20160101135A1 (en) 2016-04-14
EP3203835A1 (fr) 2017-08-16
US20160192639A1 (en) 2016-07-07
US20230077597A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
US20230077597A1 (en) Method and composition for hypothermic storage of placental tissue
US20220296778A1 (en) Allogeneic microvascular tissue for soft tissue treatments
AU2014228022B2 (en) Preparations derived from placental materials of making and using same
US11083758B2 (en) Placental membrane preparations and methods of making and using same for regenerating cartilage and spinal intervertebral discs
US20200260720A1 (en) Preservation of biomaterial properties and methods of storing
US20220040378A1 (en) Wound care treatment and methods of making and using same
US9616093B2 (en) Placental membrane preparation and methods of making and using same

Legal Events

Date Code Title Description
AS Assignment

Owner name: NUTECH MEDICAL, INC., ALABAMA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VINES, JEREMY B.;MOWRY, KATIE C.;WALTHALL, HOWARD P., JR.;REEL/FRAME:033905/0430

Effective date: 20141007

AS Assignment

Owner name: SILICON VALLEY BANK, MASSACHUSETTS

Free format text: SECURITY INTEREST;ASSIGNOR:PRIME MERGER SUB, LLC;REEL/FRAME:041767/0804

Effective date: 20170324

AS Assignment

Owner name: SILICON VALLEY BANK, MASSACHUSETTS

Free format text: SECURITY INTEREST;ASSIGNOR:PRIME MERGER SUB, LLC;REEL/FRAME:046131/0325

Effective date: 20180607

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: PRIME MERGER SUB, LLC, ALABAMA

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:NUTECH MEDICAL, INC.;PRIME MERGER SUB, LLC;REEL/FRAME:048860/0093

Effective date: 20170324

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: SILICON VALLEY BANK, CALIFORNIA

Free format text: TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT;ASSIGNOR:PRIME MERGER SUB, LLC;REEL/FRAME:057112/0703

Effective date: 20210806